Advanced mast cell disease: an Italian Hematological Multicenter experience.

Livio Pagano, Caterina Giovanna Valentini, Morena Caira

Risultato della ricerca: Contributo in rivistaArticolo in rivista


The aim of the study is to evaluate clinical features, treatments and outcome of patients with systemic mast cell disease (MCD) who arrived to the attention of hematologists. A retrospective study was conducted over 1995–2006 in patients admitted in 18 Italian hematological divisions. Twenty-four cases of advanced MCD were collected: 12 aggressive SM (50%), 8 mast cell leukemia (33%), 4 SM with associated clonal non-mast cell-lineage hematologic disease (17%). Spleen and liver were the principal extramedullary organ involved. The c-kit point mutation D816V was found in 13/18 patients in which molecular biology studies were performed (72%). Treatments were very heterogeneous: on the whole Imatinib was administered in 17 patients, a-Interferon in 8, 2-CdA in 3; 2 patients underwent allogeneic hematopoietic stem cell transplantation. The overall response rate to Imatinib, the most frequently employed drugs, was of 29%, registering one complete remission and four partial remission; all responsive patients did not present D816V c-kit mutation. Overall three patients (12%) died for progression of disease. We conclude that MCD is characterized by severe mediator- related symptoms but with a moderate mortality rate.
Lingua originaleEnglish
pagine (da-a)483-488
Numero di pagine6
RivistaInternational Journal of Hematology
Stato di pubblicazionePubblicato - 2008


  • mastocytosis


Entra nei temi di ricerca di 'Advanced mast cell disease: an Italian Hematological Multicenter experience.'. Insieme formano una fingerprint unica.

Cita questo